With access to more data than ever before – including data from patient records, laboratory research and experiments, clinical studies and decentralised trials, and scientific publications – now is the time for the industry to modernise, become data-led and boost patient experience.
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumours.
Datopotamab deruxtecan is the first antibody drug conjugate to demonstrate statistically significant improvement in PFS over docetaxel in this setting of high unmet need.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy setting.
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus Imfinzi showed a confirmed objective response rate of 79%. Two ongoing Phase III trials are evaluating datopotamab deruxtecan in patients with triple-negative breast cancer.
Imfinzi reduced the risk of disease progression or death by 29% vs. chemotherapy. First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP inhibition in advanced or recurrent endometrial cancer.
At AstraZeneca, we have the ambition to redefine the backbone of current cancer treatment – chemotherapy and radiotherapy regimens – with our discovery platform that delivers highly targeted antibody-drug conjugates (ADCs) and radioconjugates directly into cancer cells.
Preferences
Would you like to share some personal information with us so we can improve your experience on Researchalize.org?
